CLAIMS

1. Use of ulipristal acetate or any metabolite thereof in the manufacture of a medicament for the treatment of uterine fibroids in a therapeutically effective amount, wherein said ulipristal acetate or any metabolite thereof is to be administered in subsequent treatment periods and a treatment period lasts 2-6 months and each treatment period is followed by a drug-free period.

2. Use of ulipristal acetate or any metabolite thereof according to claim 1 wherein a treatment period lasts 2-4 months.

3. Use of ulipristal acetate or any metabolite thereof according to of any claims 1-2 wherein a treatment period lasts 12 weeks.

4. Use of ulipristal acetate or any metabolite thereof according to any claims 1-3 wherein a drug-free period comprises at least one menstruation cycle.

5. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-4 wherein a drug-free period comprises at least two menstruation cycles.

6. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-5 wherein a drug-free period comprises at least three menstruation cycles.

7. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-6 wherein a drug-free period is not more than 6 months.

8. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-7 wherein said ulipristal acetate or any metabolite thereof is to be administered daily.

9. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-8 wherein ulipristal acetate or any metabolite thereof is to be administered in a daily amount of 5-15 mg.

10. Use of ulipristal acetate according to any of claims 1-9 wherein ulipristal acetate is to be administered in a daily amount of 10 mg.

11. Use of ulipristal acetate or any metabolite thereof in combination with a progestin in the manufacture of a medicament for the treatment of uterine fibroids wherein ulipristal acetate or any metabolite thereof is to be administered for a treatment period

of 2-6 months and progestin is to be administered for a subsequent treatment period of 5-30 days.

12. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to claim 21 wherein said compounds are to be administered in a repetitive manner comprising the followings:

    a, administering ulipristal acetate;

    b, thereafter administering progestin;

    c, thereafter a drug-free period.

13. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-22 wherein progestin is selected from the group comprising derivatives of 19-nortestosterone, derivatives of 17α-acetoxyprogesterone, levonorgestrel and dospirenone.

14. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-23 wherein progestin is norethisterone acetate.

15. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to claim 24 wherein norethisterone acetate is to be administered in a daily amount of 5-15 mg.

16. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 24-25 wherein norethisterone acetate is to be administered in a daily amount of 10 mg.

17. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-26 wherein ulipristal acetate or any metabolite thereof is to be administered in a daily amount of 5-15 mg.

18. Use of ulipristal acetate in combination with a progestin according to any of claims 21-27 wherein ulipristal acetate is to be administered in a daily amount of 10 mg.

19. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-28 wherein ulipristal acetate or any metabolite thereof is to be administered for a treatment period of 2-4 months.

20. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-29 wherein ulipristal acetate or any metabolite thereof is to be administered for a treatment period of 12 weeks.

21. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 21-30 wherein progestin is to be administered for a treatment period of 10 days.

22. Use of ulipristal acetate in combination with a progestin according to any of claims 24-31 wherein ulipristal acetat is to be administered for a treatment period of 12 weeks and norethisterone acetate is to be administered for a treatment period of 10 days.

23. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 22-32 wherein a drug-free period comprises at least one menstruation cycle.

24. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 22-33 wherein a drug-free period comprises at least two menstruation cycles.

25. Use of ulipristal acetate or any metabolite thereof in combination with a progestin according to any of claims 22-34 wherein a drug-free period comprises at least three menstruation cycles.

CLAIMS:

1. Use of ulipristal acetate or any metabolite thereof in the manufacture of an oral medicament for the treatment of uterine fibroids in a therapeutically effective amount, wherein said ulipristal acetate or any metabolite thereof is to be administered in subsequent treatment periods and a treatment period lasts 2-6 months and each treatment period is followed by a drug-free period.
2. Use of ulipristal acetate or any metabolite thereof according to claim 1 wherein a treatment period lasts 2-4 months.
3. Use of ulipristal acetate or any metabolite thereof according to of any claims 1-2 wherein a treatment period lasts 12 weeks.
4. Use of ulipristal acetate or any metabolite thereof according to any claims 1-3 wherein a drug-free period comprises at least one menstruation cycle.
5. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-4 wherein a drug-free period comprises at least two menstruation cycles.
6. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-5 wherein a drug-free period comprises at least three menstruation cycles.
7. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-6 wherein a drug-free period is not more than 6 months.
8. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-7 wherein said ulipristal acetate or any metabolite thereof is to be administered orally daily.
9. Use of ulipristal acetate or any metabolite thereof according to any of claims 1-8 wherein ulipristal acetate or any metabolite thereof is to be administered orally in a daily amount of 5-15 mg.
10. Use of ulipristal acetate according to any of claims 1-9 wherein ulipristal acetate is to be administered orally in a daily amount of 10 mg.